NTLA
Price
$7.91
Change
+$0.33 (+4.35%)
Updated
Jun 6, 10:58 AM (EDT)
Capitalization
784.13M
55 days until earnings call
REVB
Price
$0.81
Change
-$0.07 (-7.95%)
Updated
Jun 5 closing price
Capitalization
3.75M
Interact to see
Advertisement

NTLA vs REVB

Header iconNTLA vs REVB Comparison
Open Charts NTLA vs REVBBanner chart's image
Intellia Therapeutics
Price$7.91
Change+$0.33 (+4.35%)
Volume$4.92K
Capitalization784.13M
Revelation Biosciences
Price$0.81
Change-$0.07 (-7.95%)
Volume$1.26M
Capitalization3.75M
NTLA vs REVB Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. REVB commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Buy and REVB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (NTLA: $7.57 vs. REVB: $0.81)
Brand notoriety: NTLA and REVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 100% vs. REVB: 87%
Market capitalization -- NTLA: $784.13M vs. REVB: $3.75M
NTLA [@Biotechnology] is valued at $784.13M. REVB’s [@Biotechnology] market capitalization is $3.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileREVB’s FA Score has 2 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • REVB’s FA Score: 2 green, 3 red.
According to our system of comparison, REVB is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while REVB’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • REVB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than REVB.

Price Growth

NTLA (@Biotechnology) experienced а +1.61% price change this week, while REVB (@Biotechnology) price change was -7.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

NTLA is expected to report earnings on Jul 31, 2025.

REVB is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($784M) has a higher market cap than REVB($3.75M). NTLA YTD gains are higher at: -35.077 vs. REVB (-88.951). REVB has higher annual earnings (EBITDA): -7.95M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. REVB (6.5M). REVB has less debt than NTLA: REVB (0) vs NTLA (119M). NTLA has higher revenues than REVB: NTLA (45.6M) vs REVB (0).
NTLAREVBNTLA / REVB
Capitalization784M3.75M20,896%
EBITDA-530.8M-7.95M6,679%
Gain YTD-35.077-88.95139%
P/E RatioN/AN/A-
Revenue45.6M0-
Total Cash504M6.5M7,755%
Total Debt119M0-
FUNDAMENTALS RATINGS
NTLA: Fundamental Ratings
NTLA
OUTLOOK RATING
1..100
3
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
90
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NTLAREVB
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
67%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
64%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 16 days ago
70%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGAAX23.27N/A
N/A
Virtus SGA Global Growth A
TRCVX26.86N/A
N/A
Nuveen Large Cap Value Idx Retire
PKSAX50.46N/A
N/A
Virtus KAR Small-Cap Core A
JGEMX12.39N/A
N/A
JHancock Global Equity R6
MLMAX21.55N/A
N/A
Morgan Stanley Instl Global Core A

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.30%
VCYT - NTLA
69%
Closely correlated
-1.17%
CRSP - NTLA
66%
Loosely correlated
+1.37%
BEAM - NTLA
64%
Loosely correlated
-0.87%
RXRX - NTLA
57%
Loosely correlated
-7.13%
ABCL - NTLA
55%
Loosely correlated
-2.27%
More

REVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, REVB has been loosely correlated with GNPX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if REVB jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REVB
1D Price
Change %
REVB100%
-7.85%
GNPX - REVB
48%
Loosely correlated
-2.19%
TCRT - REVB
46%
Loosely correlated
+0.79%
OGEN - REVB
35%
Loosely correlated
-4.59%
IMUX - REVB
33%
Loosely correlated
-1.38%
TOVX - REVB
31%
Poorly correlated
+2.84%
More